Pacira shares slide 3.7% on earnings miss, margin squeeze
Adjusted EBITDA plunges 38% as R&D and SG&A costs surge on AmacaThera licensing
Pacira BioSciences shares fell 3.7% in Thursday trading after the pain management specialist reported fourth-quarter earnings that missed analyst expectations despite a revenue beat, underscoring mounting margin pressure from rising research and development costs.
The Parsippany, New Jersey-based company reported adjusted earnings per share of 57 cents for the final three months of 2025, falling short of the 65-cent consensus estimate from Wall Street analysts, according to the company's earnings announcement. The miss came even as revenue of $196.9 million exceeded expectations by 8%, compared to the $182.3 million target.
The earnings shortfall reflected a sharp deterioration in profitability, with adjusted EBITDA plunging 38% year-over-year to $38.7 million. Operating expenses surged across the board, with research and development costs jumping 57% driven primarily by the in-licensing of AmacaThera, an emerging pain management therapy. Sales, general and administrative expenses rose 28%, attributed to increased litigation costs and business development expenditures.
"We delivered record-high EXPAREL sales with volume growth of 7 percent, marking our strongest fourth quarter performance in three years," the company stated in a press release. EXPAREL is Pacira's flagship non-opioid pain medication used in post-surgical settings.
Despite the quarterly revenue beat, investors focused on the guidance for 2026, which projects revenue of $745 million to $770 million. That implies growth of just 3% to 6% over 2025 levels, suggesting a deceleration for a company that has historically relied on strong EXPAREL volume growth to drive expansion.
The guidance disappointment and margin compression have pressured shares, which now trade at $22.59, below their 50-day moving average of $23.18 and well off the 52-week high of $27.64 reached earlier this year. The stock has lost nearly 18% of its value over the past six months.
Pacira's forward price-to-earnings ratio of 7.36 suggests investors have already priced in significant growth headwinds, well below the trailing P/E of 49.81. Analysts maintain a consensus target price of $29.71, representing nearly 32% upside from current levels, though the earnings miss could prompt revisions in coming weeks.
The company's balance sheet remains relatively strong with approximately $1 billion in market capitalization and no dividend payments, preserving cash for continued investment in its pipeline. However, the aggressive spending on R&D—particularly the AmacaThera licensing deal—raises questions about the timeline for returns on investment.
AmacaThera represents a strategic bet on expanding Pacira's portfolio beyond EXPAREL, which faces increasing competition in the non-opioid pain management market. The in-licensing costs contributed to the quarterly earnings shortfall but could provide longer-term growth catalysts if clinical development progresses successfully.
With EXPAREL volume growth showing signs of resilience at 7%, Pacira's core business remains intact. However, the market's reaction to the earnings miss reflects concerns about whether the company can maintain profitability while investing in new therapies to diversify its revenue streams.
The company's fiscal year 2025 revenue reached $716.8 million according to trailing twelve-month data, placing Pacira as a mid-cap player in the specialty pharmaceutical space. Institutional investors hold 116% of shares outstanding, indicating significant ownership by large money managers who will scrutinize the margin trajectory in coming quarters.
As Pacira navigates the transition from a single-product company to a diversified pain management portfolio, investors will be watching closely for signs that rising investment spending translates into meaningful revenue contributions from new products beyond EXPAREL.